With the rise of multidrug resistance,
Pseudomonas aeruginosa infections require alternative
therapeutics. The injectisome (iT3SS) and flagellar (fT3SS)
type III secretion systems are 2
virulence factors associated with poor clinical outcomes. iT3SS translocates toxins, rod, needle, or regulator
proteins, and
flagellin into the host cell cytoplasm and causes cytotoxicity and NLRC4-dependent
inflammasome activation, which induces
interleukin 1β (IL-1β) release and reduces
interleukin 17 (IL-17) production and bacterial clearance. fT3SS ensures bacterial motility, attachment to the host cells, and triggers
inflammation. INP1855 is an iT3SS inhibitor identified by in vitro screening, using Yersinia pseudotuberculosis Using a mouse model of P. aeruginosa pulmonary
infection, we show that INP1855 improves survival after
infection with an iT3SS-positive strain, reduces bacterial pathogenicity and dissemination and IL-1β secretion, and increases
IL-17 secretion. INP1855 also modified the
cytokine balance in mice infected with an iT3SS-negative, fT3SS-positive strain. In vitro, INP1855 impaired iT3SS and fT3SS functionality, as evidenced by a reduction in secretory activity and flagellar motility and an increase in
adenosine triphosphate levels. As a result, INP1855 decreased cytotoxicity mediated by toxins and by
inflammasome activation induced by both laboratory strains and clinical isolates. We conclude that INP1855 acts by dual inhibition of iT3SS and fT3SS and represents a promising therapeutic approach.